Avtor/Urednik | Brecelj, J; Logar-Car, G; Sedmak, M; Orel, R; Ferkolj, I; Golli, T | |
Naslov | Deklica z neodzivno kronično vnetno črevesno boleznijo - prvo poročilo o zdravljenju otroka z infliximabom v Sloveniji | |
Prevedeni naslov | A girl with a refractory chronic inflammatory bowel disease - first report of the treatment of a child with infliximab in Slovenia | |
Tip | članek | |
Vir | Slov Pediatr | |
Vol. in št. | Letnik 10, št. 3 | |
Leto izdaje | 2003 | |
Obseg | str. 169-72 | |
Jezik | slo | |
Abstrakt | Infliximab is anti tumour necrosis factor-alpha (TNF-alpha) monoclonal antibody. In the field of gastroenterology it is indicated for the treatment of patients with medically refractory as well as fistulizing Crohn disease. The limitations of its use in the paediatric population are due to the possibility of serious side effects and unknown long-term consequences. We present a case report of the first treatment of refractory inflammatory bowel disease with infliximab in a child in our center. The treatment in a ten years old girl was uneventful. The clinical response was visible in a few days. Gradually we discontinued the corticosteroid therapy. She has maintained remission for seventeen weeks after the infusion of infliximab. We discuss the experiences of other medical centers in comparison to our treatment course. | |
Izvleček | Infliximab je monoklonsko protitelo proti tumorskem nekrotizirajočem faktorju alfa (TNF-alfa). V gastroenterologiji je infliximab učinkovit za zdravljenje na standardno zdravljenje neodzivne in fistulizirajoče Crohnove bolezni. Omejitve za uporabo pri otrocih so možni hudi neželeni učinki in neznane dolgoročne posledice zdravljenja. V prispevku poročamo o prvem primeru zdravljenja neodzivne vnetne črevesne bolezni z infliximabom pri otroku pri nas. Pri desetletni deklici je zdravljenje potekalo brez zapletov. V nekaj dneh je nastopilo klinično izboljšanje. Zdravljenje s kortikosteroidi smo lahko postopoma ukinili. V remisiji je bila do sedemnajst tednov po prejetju infliximaba. V razpravljanju prikazujemo nekatere izkušnje iz tujih centrov in jih primerjamo z našimi. | |
Deskriptorji | INFLAMMATORY BOWEL DISEASES TUMOR NECROSIS FACTOR ANTIBODIES, MONOCLONAL CHILD TREATMENT OUTCOME |